fluocinolone


Also found in: Dictionary, Financial, Encyclopedia.
Related to fluocinolone: Fluocinolone acetonide

fluocinolone

 [floo″o-sin´o-lōn]
a synthetic corticosteroid used topically as f. acetonide for the relief of inflammation and pruritus in certain dermatoses.

fluocinolone

(floo-oh-sin-oh-lone) ,

Capex

(trade name),

Derma-Smoothe/FS

(trade name),

Fluoderm

(trade name),

Synalar

(trade name)

Classification

Therapeutic: anti inflammatories steroidal
Pharmacologic: corticosteroids
Pregnancy Category: C

Indications

Management of inflammation and pruritis associated with various allergic/immunologic skin problems.

Action

Suppresses normal immune response and inflammation.

Therapeutic effects

Suppression of dermatologic inflammation and immune processes.

Pharmacokinetics

Absorption: Minimal. Prolonged use on large surface areas, application of large amounts, or use of occlusive dressings may increase systemic absorption.
Distribution: Remains primarily at site of action.
Metabolism and Excretion: Usually metabolized in skin.
Half-life: Unknown.

Time/action profile (response depends on condition being treated)

ROUTEONSETPEAKDURATION
Topicalmin–hrshrs–dayshrs–days

Contraindications/Precautions

Contraindicated in: Hypersensitivity or known intolerance to corticosteroids or components of vehicles (ointment or cream base, preservative, alcohol); Untreated bacterial or viral infections.
Use Cautiously in: Hepatic dysfunction; Diabetes mellitus, cataracts, glaucoma, or tuberculosis (use of large amounts of high-potency agents may worsen condition); Patients with pre-existing skin atrophy; Pregnancy, lactation, or children (chronic high-dose usage may result in adrenal suppression in mother, growth suppression in children; children may be more susceptible to adrenal and growth suppression).

Adverse Reactions/Side Effects

Dermatologic

  • allergic contact dermatitis
  • atrophy
  • burning
  • dryness
  • edema
  • folliculitis
  • hypersensitivity reactions
  • hypertrichosis
  • hypopigmentation
  • irritation
  • maceration
  • miliaria
  • perioral dermatitis
  • secondary infection
  • striae

Miscellaneous

  • adrenal suppression (use of occlusive dressings, long-term therapy)

Interactions

Drug-Drug interaction

None significant.

Route/Dosage

Topical (Adults) Apply to affected area(s) 2–5 times daily (depends on preparation and condition being treated).
Topical (Children ≥2 yr) Apply to affected area(s) 1–2 times daily (depends on product, preparation, and condition being treated).

Availability (generic available)

Cream: 0.01%, 0.025%
Ointment: 0.025%
Solution: 0.01%
Shampoo: 0.01%
Oil: 0.01%
In combination with: hydroquinone and tretinoin (Tri-Luma). See combination drugs.

Nursing implications

Nursing assessment

  • Assess affected skin before and daily during therapy. Note degree of inflammation and pruritus. Notify health care professional if symptoms of infection (increased pain, erythema, purulent exudate) develop.
  • Lab Test Considerations: Periodic adrenal function tests may be ordered to assess degree of hypothalamic-pituitary-adrenal (HPA) axis suppression in chronic topical therapy if suspected. Children and patients with dose applied to a large area, using an occlusive dressing, or using high-potency products are at highest risk for HPA suppression.
    • May cause increased serum and urine glucose concentrations if significant absorption occurs.

Potential Nursing Diagnoses

Risk for impaired skin integrity (Indications)
Risk for infection (Side Effects)
Deficient knowledge, related to medication regimen (Patient/Family Teaching)

Implementation

  • Choice of vehicle depends on site and type of lesion. Ointments are more occlusive and preferred for dry, scaly lesions. Creams should be used on oozing or intertriginous areas, where the occlusive action of ointments might cause folliculitis or maceration. Creams may be preferred for aesthetic reasons even though they may be more drying to skin than ointments. Gels, aerosols, lotions, and solutions are useful in hairy areas.
  • Topical: Apply ointments, creams, orsolutions sparingly as a thin film to clean, slightly moist skin. Wash hands immediately after application. Apply occlusive dressing only if specified by health care professional.
    • Apply shampoo oroil to hair by parting hair and applying a small amount to affected area. Rub in gently. Protect area from washing, clothing, or rubbing until medication has dried. Hair may be washed as usual but not immediately after applying medication.

Patient/Family Teaching

  • Instruct patient on correct technique of medication administration. Emphasize importance of avoiding the eyes. If a dose is missed, it should be applied as soon as remembered unless almost time for the next dose.
  • Caution patient to use only as directed. Avoid using cosmetics, bandages, dressings, or other skin products over the treated area unless directed by health care professional.
  • Advise parents of pediatric patients not to apply tight-fitting diapers or plastic pants on a child treated in the diaper area; these garments work like an occlusive dressing and may cause more of the drug to be absorbed.
  • Advise patient to consult health care professional before using medicine for condition other than indicated.
  • Caution women that medication should not be used extensively, in large amounts, or for protracted periods if they are pregnant or planning to become pregnant.
  • Instruct patient to inform health care professional if symptoms of underlying disease return or worsen or if symptoms of infection develop.

Evaluation/Desired Outcomes

  • Resolution of skin inflammation, pruritus, or other dermatologic conditions.

fluocinolone

/flu·o·cin·o·lone/ (floo″ah-sin´ah-lōn) a synthetic corticosteroid used topically as f. acetonide for the relief of inflammation and pruritus in certain dermatoses.

fluocinolone

A powerful CORTICOSTEROID drug used for external applications. A brand name is Synalar. It is marketed with other ingredients as Synalar C and Synalar N.
References in periodicals archive ?
Then, the report explores the company profile of the key-players in the Fluocinolone Acetonide market, analyzing their current and past product specifications.
Then, the report reviews the past market condition of the Global and Chinese Fluocinolone Acetonide industry over the review period of 2010-2015, analyzing crucial figures of industry wide production, consumption and supply of Fluocinolone Acetonide within the review period.
Kompella, of the University of Nebraska Medical Center in Omaha, reported that they found that Fluocinolone inhibited VEGF expression in ARPE-19 cells via its glucorcorticoid receptor activity.
Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema.
Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema.
Reversable HPA axis (adrenal function) suppression may result from exposure to the topical corticosteroid, fluocinolone acetonide, so discontinue use if signs and symptoms of this condition occur.
Medidur is a tiny insert, injected intra-vitreally during an in-office procedure, which is being studied as a way to deliver a very low dose of fluocinolone acetonide (FA), a corticosteroid, to the retina for up to three years as a treatment for DME.
ATLANTA -- Alimera Sciences, a privately held ophthalmic pharmaceutical company, and pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) today announced that enrollment has begun for the first human (a)pharmacokinetic (PK) study of fluocinolone acetonide (FA) in Medidur[TM], the companies' investigational product for the treatment of diabetic macular edema (DME).
Alimera is currently conducting a phase III clinical trial of fluocinolone acetonide in the Medidur[TM] drug delivery system for the treatment of diabetic macular edema.
Its primary product, ILUVIEN, is an intravitreal implant containing fluocinolone acetonide (FAc), a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease.
Alimera is currently conducting a phase 3 clinical trial of fluocinolone acetonide in the Medidur[TM] drug delivery system for the treatment of diabetic macular edema.